Showing 1381-1390 of 4730 results for "".
DermwireTV — Revance’s Neurotoxin Promising, Celebs Fight Melanoma with L’Oreal
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-revance-rsquo-s-neurotoxin-promising-celebs-fight-melanoma-with-l-rsquo-oreal/19138/In this weeks DermwireTV, patient safety is explored, L'Oreal supports melanoma research and Revance reports positive data for novel neurotoxin.When Topicals Fail: The New IPC Consensus Every Clinician Should Know
https://practicaldermatology.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/Review IPC’s 2025 consensus guidance on reclassifying psoriasis severity and redefining failure of topical therapies.Regression in Primary Melanomas: Histologic Factors and Prognosis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/regression-in-primary-melanomas-histologic-factors-and-prognosis/21367/Regression was once thought to be a negative prognostic factor in primary melanomas, but new findings suggest otherwise.Currents: Updates On Skin Cancer
https://practicaldermatology.com/topics/skin-cancer-photoprotection/currents-updates-on-skin-cancer/23482/Acne-Focused Skin Care: A Win-Win
https://practicaldermatology.com/topics/skin-cancer-photoprotection/acne-focused-skin-care-a-win-win/20653/Currents: Eczema
https://practicaldermatology.com/topics/atopic-dermatitis/currents-eczema-1/23743/Currents: Patient-Focused Approaches to Eczema
https://practicaldermatology.com/topics/atopic-dermatitis/currents-patient-focused-approaches-to-eczema/23444/From the Neck Down
https://practicaldermatology.com/topics/practice-management/from-the-neck-down/20781/Exploring other uses for Allergan's KybellaCosmetics Challenge
https://practicaldermatology.com/topics/general-topics/cosmetics-challenge/21793/Soliton’s RAP Technology for Cellulite
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/solitons-rap-technology-for-cellulite/23465/An inside look at the latest device designed to target cellulite.